Skip Ribbon Commands
Skip to main content

Advanced TACE

Our ultimate goal by taking TACE to the next level: to Prolong HCC patients Life expectancy  

Improving complete response rates and maintaining this response lead to an increase in overall survival1

  • DEM-TACE treatments reach high complete response rates:1

  • 60% Complete response rate leading to almost 3 years overall survival (35.8month) (n=586 patients)1

  • Even when multiple treatments are required for larger , complex tumours2

  • 20% of patients achieved complete response after 3rd or 4th TACE procedures  (n=97)2


  1. De Baere T et al. Presented at ESMO GI 2020 (pooled analyses)

  2. de Baere T et al. Cancers (Basel) 2020;12:E3405 (PARIS registry)

Breaking new data with Advanced TACE

Watch the videos below - which are of presentations from ECIO 2021.

What the evidence says

Discover our clinical evidence and case studies concerning this topic.

Upcoming events

Mauris sed purus volutpat, convallis nibh ac, feugiat lorem. Sed dignissim arcu eulala.

ECIO 2023
April 16 - 19
All events

Do you need more info about this product?

Our sales representatives are here for you.

Contact us
Send us a message
I have read and accept Terumo Privacy And Cookies Policy and the Terms Of Use*
I wish to receive information and marketing updates from Terumo.
* mandatory fields

Thank you for contacting us!

We typically respond within 2 business days and will come back to you as soon as possible.

Are you a healthcare professional?

This webpage can include promotional content regarding one or several products of Terumo Europe, or some procedures concerning the use or implantation of such products. This webpage is exclusively intended for healthcare professionals and is in no event directed to the general public

For Pharmaceutical Professionals interested in our B2B products portfolio, please visit Terumo Pharmaceutical Solutions.